Health · Pharma & Biotech · 7 hrs ago
Marrow Therapeutics raises $173 million to develop sickle cell treatment
Marrow Therapeutics raised $173 million to develop treatments for severe blood diseases.
The startup, led by CEO Romesh Subramanian, is developing a lead drug called MAR-101 for sickle cell disease and beta thalassemia.
Current gene therapies can have long-lasting effects, but they require patients’ stem cells to be modified in a lab and chemotherapy before treatment.
They are also available only at specially equipped centers and cost millions of dollars, which has contributed to slow uptake.
MAR-101 is designed as an injection that delivers a small RNA molecule to bone marrow cells, prompting them to make fetal hemoglobin.
Marrow hopes the treatment can be as effective as gene therapy while being simpler to manufacture and access.
The company plans to use its funding to advance MAR-101 and build manufacturing capacity, but it has not said when clinical trials will begin.
Marrow Therapeutics launched with $173 million in Series A and B funding to develop a treatment for sickle cell disease.
The startup was founded by biotech entrepreneur Romesh Subramanian.
It aims to develop an infusion that could be as effective as gene therapy without its drawbacks.
The funding came from Scion Life Sciences, venBio, OrbiMed and others.
- Who
- Marrow Therapeutics, founded by biotech entrepreneur Romesh Subramanian.
- What
- The startup launched with $173 million in Series A and B funding to pursue a sickle cell treatment.
- When
- Subramanian announced the founding on Tuesday, November 17, 2026.
- Where
- Not stated.
- Why
- To pursue an infusion for sickle cell disease that could be as effective as gene therapy while avoiding its drawbacks.
This story does not have two clearly opposing sides.
The FDA approved two gene therapies for sickle cell disease.
Romesh Subramanian announced Marrow Therapeutics’ founding and its $173 million in Series A and B funding.
- Funding
- $173 million in Series A and B
- Founder
- Romesh Subramanian
- Investors
- Scion Life Sciences, venBio, OrbiMed and others
- Target disease
- Sickle cell disease
- Treatment approach
- An infusion intended to be as effective as gene therapy
3 sources
What people are saying
We expect it to be as good as [gene therapy] in patients
but to be proven for sure.